Tirzepatide
Dual GLP-1 / GIP receptor agonist
Dual GLP-1 / GIP receptor agonist for appetite control, glucose regulation, and sustained weight loss. Available in 10mg, 30mg, and 60mg vials.
Important Research Notice
Research use only. Not for human consumption. This product is intended solely for laboratory research and educational applications. It is not designed for use in the diagnosis, treatment, cure, or prevention of any disease or medical condition. By purchasing this product, you acknowledge that this product is intended for research use only and agree to use it in accordance with all applicable laws and regulations.
People also buy
Slimetry Capsules - 26.15mg
Slimetry Capsules (GLP-1S / 5-Amino-1MQ / BPC-157)This unique combination is studied for its potential influence on metabolic pathways, weig
5-Amino-1 MQ Capsules - 50mg
5-Amino-1 MQ is a small molecule compound that has been studied for its potential role in regulating fat metabolism and energy balance. It i
Bacteriostatic Water
Reconstitution solution
Gut Inflammation Capsules - 2mg
2mg Capsules (BPC-157 / TB-500 / KPV / Larazotide)Each capsule delivers a balanced 2mg blend containing BPC-157 (500mcg), TB-500 (500mcg), K
Wolverine Strips
BPC-157 + TB-500 per strip
GLOW Strips
BPC-157 + TB-500 + GHK-Cu per strip
CJC-1295 / Ipamorelin Strips
CJC-1295 + Ipamorelin per strip
Wolverine
Recovery peptide blend
References
- Tirzepatide - Peptide Center guide
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityThe New England journal of medicine, 2024
- Tirzepatide Once Weekly for the Treatment of ObesityThe New England journal of medicine, 2022
- Tirzepatide for Obesity Treatment and Diabetes PreventionThe New England journal of medicine, 2025
- Tirzepatide as Compared with Semaglutide for the Treatment of ObesityThe New England journal of medicine, 2025
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesThe New England journal of medicine, 2021
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityThe New England journal of medicine, 2025
Ready to start with Tirzepatide?
Take our eligibility quiz to see if this treatment is right for you.
Get Started